The U.S. Food and Drug Administration has granted Orphan Drug Designation to GT-GLA-S03, an investigational redosable cell therapy for classic Fabry disease developed by Glafabra Therapeutics. The designation, announced March 12, 2026, provides seven years of market exclusivity upon approval, $4.68 million in fee exemptions, and tax credits, de-risking the program and signaling FDA validation of the underlying science.
GT-GLA-S03 is built on Glafabra’s proprietary Live-cel™ platform and has demonstrated safety and efficacy in a pilot study with five years of clinical data. According to the company, a single dose of GT-GLA-S03 replaces approximately 130 clinic visits over five years, and the therapy is designed to be redosable if needed. The clinical data were published in Clinical and Translational Medicine (PMID 39794302) and supported by earlier work in Nature Communications (PMID 33633114) and clinical trial NCT02800070.
“FDA Orphan Drug Designation unlocks the path to market,” said Dr. Chris Hopkins, CEO of Glafabra Therapeutics. “Five years of clinical data shows GT-GLA-S03 is safe, effective, and durable — replacing 130 clinic visits over five years with a single dose, and redosable when needed.” The company emphasized that the designation does not indicate that GT-GLA-S03 is safe or effective for Fabry disease, as it remains an investigational therapy not approved by the FDA.
Beyond Fabry disease, the Live-cel™ platform is in preclinical development for Pompe disease (GT-GAA-S04) and Gaucher disease (GT-GBA1-S05), targeting a combined patient population of two million with no durable treatment options today. Glafabra Therapeutics, based in Park City, Utah, was co-founded by Dr. Chris Hopkins, Dr. Jeffrey Medin, and Dr. Ronan Foley, and holds issued patent 12,540,336 covering its cell therapy approach.
The Orphan Drug Designation provides financial and regulatory incentives that can accelerate development for rare diseases. For Glafabra, it represents a critical step in advancing a new class of redosable cell therapies for lysosomal storage disorders, potentially transforming the treatment landscape for patients with Fabry disease and beyond.
